GlassScriptPhysician profile
Hiren K Patel
NPI 1114951225
$16,134.07
in general payments reported to CMS, 2019-2025
41 companies · $3,051 in 2025
The $3,051 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $488 · 2021: $898 · 2022: $1,300 · 2023: $4,856 · 2024: $4,038 · 2025: $3,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $6,125 · Food and Beverage: $4,213 · Travel and Lodging: $1,501 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $6,125.00 |
| Food and Beverage | $4,212.69 |
| Travel and Lodging | $1,500.66 |
| Education | $107.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,265.97 | 2021-2024 | |
| Abbott Laboratories | $2,497.40 | 2019-2025 | Triclip, Navitor, Aveir |
| Penumbra, INC. | $935.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $546.62 | 2022-2025 | |
| Boston Scientific Corporation | $473.80 | 2021-2025 | Rhythmia Mapping System, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Merck Sharp & Dohme LLC | $449.52 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Amgen INC. | $400.51 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $399.25 | 2019-2024 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $351.07 | 2019-2025 | Lifevest |
| Philips North America LLC | $344.91 | 2023-2025 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und, Affiniti Cvx |
| Sanofi-Aventis U.S. LLC | $317.97 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $313.41 | 2019-2025 | |
| Esperion Therapeutics, INC. | $302.05 | 2020-2024 | Nexletol |
| Cvrx, INC. | $272.68 | 2022-2025 | Barostim Neo System |
| Abiomed | $234.19 | 2019-2025 | Impella |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.87 | 2019-2025 | Jardiance |
| Pfizer INC. | $207.54 | 2019-2025 | |
| Biotronik INC. | $189.11 | 2019-2024 | Biomonitor |
| Amarin Pharma, INC. | $183.08 | 2019-2021 | |
| Novo Nordisk INC | $134.60 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $125.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.13 | 2022-2025 | Camzyos |
| Cardiva Medical, INC. | $92.21 | 2024 | Optowire |
| Biosense Webster, INC. | $89.95 | 2025 | Carto 3 |
| W. L. Gore & Associates, INC. | $85.27 | 2022-2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Alnylam Pharmaceuticals INC. | $76.44 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $63.01 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $58.57 | 2020-2022 | |
| Bridgebio Pharma, INC. | $57.58 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $49.02 | 2024-2025 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $39.22 | 2020-2023 | Sapien 3 Ultra Resilia |
| Ascensia Diabetes Care US INC. | $36.97 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $30.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $30.53 | 2019-2024 | Evkeeza |
| Heartflow, INC. | $28.61 | 2024 | |
| Silk Road Medical, INC. | $27.41 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Scpharmaceuticals INC. | $21.63 | 2025 | |
| Cordis US Corp. | $20.41 | 2025 | |
| Innovation Technologies INC | $15.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.11 | 2021 | |
| Cashflow Solutions, LLC | $10.71 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.